

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Predicting Opioid Induced Oversedation in Hospitalized Patients: A Multicenter Observational Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-051663
Article Type:	Original research
Date Submitted by the Author:	24-Mar-2021
Complete List of Authors:	Garrett, John; Baylor University Medical Center at Dallas, Department of Emergency Medicine Vanston , Anneliese ; Baylor University Medical Center at Dallas Ogola, Gerald; Baylor Scott & White Research Institute da Graca, Briget; Baylor Scott & White Research Institute, Cassity, Cindy; Baylor University Medical Center at Dallas Kouznetsova, Maria; Baylor Scott & White Health Hall, Lauren R.; Baylor Scott & White Health Qiu, Taoran; Baylor Scott & White Health
Keywords:	Pain management < ANAESTHETICS, Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**Title:** Predicting Opioid Induced Oversedation in Hospitalized Patients: A Multicenter Observational Study

**Authors:**

John S. Garrett MD MRA FACEP  
Chair, Department of Emergency Medicine, Baylor University Medical Center  
[John.garrett@bswhealth.org](mailto:John.garrett@bswhealth.org)  
ORCID ID: 0000-0002-0012-7285

Anneliese Vanston BS RN  
Patient Safety Coordinator, Baylor University Medical Center  
[apvanston@gmail.com](mailto:apvanston@gmail.com)

Gerald Ogola PhD  
Biostatistician, Baylor Scott & White Research Institute  
[Gerald.ogola@bswhealth.org](mailto:Gerald.ogola@bswhealth.org)

Briget da Graca, JD, MS  
Assistant Investigator, Baylor Scott & White Research Institute  
[Briget.dagraca@bswhealth.org](mailto:Briget.dagraca@bswhealth.org)

Cindy Cassity MSN RN  
Director, Patient Safety and Value-Based Healthcare Improvement, Baylor University Medical Center  
[Cindy.cassity@bswhealth.org](mailto:Cindy.cassity@bswhealth.org)

Maria A Kouznetsova, MS, MPH, PhD  
Analytics Developer II, Baylor Scott & White Health  
[maria\\_kouznetsova@yahoo.com](mailto:maria_kouznetsova@yahoo.com)

Lauren R. Hall, PhD, MPH  
Analytics Developer II, Baylor Scott & White Health  
[lauren.hall1@bswhealth.org](mailto:lauren.hall1@bswhealth.org)

Taoran Qiu, MS  
Analytics Developer II, Baylor Scott & White Health  
[taoran.qiu@bswhealth.org](mailto:taoran.qiu@bswhealth.org)

Correspondence to:

John S. Garrett MD MRA FACEP  
Chair Department of Emergency Medicine  
Baylor University Medical Center  
3500 Gaston Avenue  
Dallas, Texas 75246  
Phone: 214-820-8646

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Email: [john.garrett@bswhealth.org](mailto:john.garrett@bswhealth.org)  
<https://orcid.org/0000-0002-0012-7285>

Word count: Abstract – 300; Text – 3085

Tables – 4

Figures – 3

References - 38

For peer review only

**ABSTRACT (300 words)**

Objectives: Opioid-induced respiratory depression (OIRD) and oversedation are rare but potentially devastating adverse events in hospitalized patients. We investigated which features predict an individual patient's risk of OIRD or oversedation; and developed a risk stratification tool that can be used to aid point-of-care clinical decision-making.

Design: Retrospective observational study

Setting: Twelve acute care hospitals in a large not-for-profit integrated delivery system

Participants: All inpatients  $\geq 18$  years admitted between July 1, 2016 and June 30, 2018 who received an opioid during their stay (163,190 unique hospitalizations).

Main outcome measures: The primary outcome was occurrence of sedation or respiratory depression severe enough that emergent reversal with naloxone was required, as determined from medical record review; if naloxone reversal was unsuccessful or if there was no evidence of hypoxic encephalopathy or death due to oversedation, it was not considered an oversedation event.

Results: Age, sex, body mass index, chronic obstructive pulmonary disease, concurrent sedating medication, renal insufficiency, liver insufficiency, opioid naïvety, sleep apnea, and surgery were significantly associated with risk of oversedation. The strongest predictor was concurrent administration of another sedating medication (adjusted hazard ratio, 95%CI = 3.88, 2.48-6.06); the most common such medications were benzodiazepines (29%), antidepressants (22%), and gamma-aminobutyric acid analog (14.7%). The c-statistic for the final model was 0.755. The 24-point Oversedation Risk Criteria (ORC) score developed from the model stratifies patients as high (>20%, 22-24 points), moderate (11-20%, 18-21 points), and low risk ( $\leq 10\%$ , <18 points).

Conclusions: The ORC risk score identifies patients at high risk for OIRD or oversedation from routinely collected data, enabling targeted monitoring for early detection and intervention. It can also be applied to preventive strategies – for example, clinical decision support offered when concurrent prescriptions for opioids and other sedating medications are entered that shows how the chosen combination impacts the patient's risk.

Keywords: oversedation, opioid-induced respiratory distress, risk score

### Strengths and limitations of this study

- This multi-hospital study is the first large study to develop a risk score for oversedation/opioid-induced respiratory depression that is applicable to all adult hospitalized patients prescribed opioids.
- All predictors used to build the novel 24-point Oversedation Risk Criteria (ORC) score presented here are routinely collected and readily available from the electronic medical record; thus, implementation will not add to clinicians' data collection burden.
- The predictors include both patient characteristics that cannot be modified and treatment choices that can; it can therefore both facilitate targeted monitoring for early detection and intervention on oversedation/opioid-induced respiratory distress events, and be used in clinical decision support tools, providing information regarding the impact of concomitant medication choice on a patient's risk for such an event.
- This is a novel risk score that should be validated in other, external case series.

## INTRODUCTION

Opioid-induced respiratory depression (OIRD) and oversedation are rare but frequently devastating side effects of opioid analgesia in hospitalized patients. In an analysis of closed malpractice claims, more than half the OIRD events resulted in death, and another 22% in severe brain damage.<sup>1</sup> Furthermore, such events are highly preventable with improved monitoring and response.<sup>1,2</sup> The challenge, however, lies in ensuring appropriate monitoring is provided. Opioid analgesia is the primary pharmacologic intervention for managing pain in hospitalized patients,<sup>3</sup> and more than half of all non-surgical patients admitted to hospitals,<sup>4</sup> and almost all patients who undergo surgery,<sup>5,6</sup> receive opioids during their stay. At these large volumes, continuous monitoring of all patients receiving opioids is not feasible: even if hospitals were to invest in the equipment necessary to provide pulse oximetry and capnography electronic monitoring<sup>7</sup> for all patients receiving opioids, issues related to alarm fatigue and staff burden<sup>8</sup> would remain significant barriers to effective monitoring.

Acknowledging the challenges to continuously monitoring all patients receiving opioids, clinical practice guidelines (for example, from the American Society of Anesthesiologists<sup>9</sup> and the American Society for Pain Management Nursing<sup>10</sup>), as well as the Joint Commission accreditation requirements addressing safe use of opioids for pain management,<sup>11</sup> include the step of identifying patients at high risk of OIRD or oversedation for enhanced monitoring. However, there is currently no agreed-upon method for assessing that risk. Multiple factors that increase patient risk – including patient demographic characteristics (such as older age<sup>12-14</sup> and female sex<sup>12,15,16</sup>), clinical characteristics (such as cardiac disease,<sup>12,17,18</sup> pulmonary disease,<sup>12,17</sup> sleep apnea,<sup>12,15-20</sup> diabetes,<sup>18,20</sup> impaired kidney function,<sup>12,15,16,18</sup> and obesity<sup>12,14,15</sup>), and opioid-related factors (higher opioid dosage,<sup>12,17,19,20</sup> route of administration<sup>12,16</sup> and concomitant use of other medications with sedative effects<sup>12,13,19,21</sup>). Survey data indicates that, while at least some of these factors are considered by most hospitals in identifying patients at high risk for OIRD and oversedation, there is substantial variation in which criteria are used.<sup>8</sup> Furthermore, simply considering the list of possible risk factors does not help clinicians quantify actual



1  
2  
3 risks for patients with multiple factors present, as it does not provide information regarding the extent to  
4  
5 which they may be additive.  
6

7 Some previous work has been done to synthesize multiple patient risk factors into clinically-  
8  
9 useful risk scores. The PRODIGY trial, for example, developed a 5-variable prediction model for OIRD,  
10  
11 using data from a prospective trial in which participants were monitored continuously via capnography  
12  
13 and pulse oximetry, but was limited to patients receiving parenteral opioids, treated on the general care  
14  
15 floor, and able to wear the continuous monitoring equipment.<sup>22 23</sup> Another risk scoring system for severe  
16  
17 opioid-related adverse events (including somnolence, respiratory depression, and cardiopulmonary  
18  
19 arrest) was developed from a US national cohort of medical hospitalizations, but did not consider  
20  
21 surgical or trauma admissions.<sup>24</sup> A risk index has also been developed and validated for serious OIRD  
22  
23 or overdose among outpatients with opioid prescriptions,<sup>25 26</sup> but has not been tested for the inpatient  
24  
25 setting (where dosages, routes of administration, and the degree of control the patient has over when  
26  
27 and how much of the medication to take, differ significantly).<sup>25 26</sup> What is thus currently missing from the  
28  
29 literature is a risk score that is applicable to all hospitalized patients. Using data from our multi-hospital  
30  
31 system, we sought to address this gap and 1) determine which features predict an individual patient's  
32  
33 risk of OIRD or oversedation; and 2) develop a risk stratification tool to determine which patients are  
34  
35 low, moderate, and high risk for OIRD or oversedation that can be used at the point-of-care to aid  
36  
37 clinical decision-making.  
38  
39  
40  
41  
42

## 43 **METHODS**

44 This study was approved by the Baylor Scott & White Research Institute's institutional review  
45  
46 board with a waiver of informed consent.  
47  
48  
49  
50

51 Study population: We considered all adult ( $\geq 18$  years) patients admitted to one of the 12 [health care  
52  
53 system] acute care hospitals in north Texas between July 1, 2016 and June 30, 2018 who received an  
54  
55 opioid during their inpatient stay.  
56  
57

1  
2  
3  
4  
5 Outcomes: The outcome of interest (“oversedation”) was defined as an occurrence of sedation or  
6  
7 respiratory depression severe enough that the primary care team felt emergent reversal with naloxone  
8  
9 was indicated. Cases in which naloxone was administered were identified from the electronic medical  
10  
11 record and individually reviewed by one of two healthcare providers via a standardized review process.  
12  
13 Discrepancies between reviewers were discussed until both reviewers agreed with final determination.  
14  
15 If naloxone administration successfully reversed the sedation event or opioid medication administered  
16  
17 as part of inpatient care was determined to be the causative etiology of sedation, the case was  
18  
19 considered an oversedation event. Cases in which reversal with naloxone was not successful or in  
20  
21 which the patient did not have evidence of hypoxic encephalopathy or death due to oversedation were  
22  
23 not considered to be oversedation events. Patients who received naloxone during the course of  
24  
25 procedural sedation were excluded from this analysis.  
26  
27  
28  
29

30  
31 Data collection: All data were extracted from the electronic medical record. Data were collected on  
32  
33 patient demographics, medical history, and clinical and admission characteristics considered to be  
34  
35 potential risk factors for oversedation, as identified in national guidelines.<sup>3</sup> Patient outcomes (discharge  
36  
37 disposition and length of stay) were also collected. All variables are listed in Table 1.  
38  
39  
40

#### 41 Statistical analysis:

42  
43 Patients’ demographic characteristics, medical history and outcomes were summarized for the  
44  
45 over-sedated and not-oversedated groups. Continuous variables were summarized by mean and  
46  
47 standard deviation or median with interquartile range, while categorical variables were summarized by  
48  
49 frequency and percent. Differences in the characteristics were assessed by t-tests or Kruskal-Wallis  
50  
51 tests for continuous data, and Chi-square tests for categorical data.  
52

53  
54 Cox proportional hazards regression model was developed to predict in-hospital risk of  
55  
56 oversedation. Survival times were defined as time from hospital admission to oversedation for patients  
57

1  
2  
3 that experienced oversedation, or time from hospital admission to discharge for patients that were  
4  
5 never oversedated during their hospital stay. To develop the risk model, we first examined a full model  
6  
7 with all potential risk factors of interest. Risk factors considered included age, sex, race, ethnicity, body  
8  
9 mass index (BMI), smoking history, indicator of concurrent administration of sedating medication,  
10  
11 surgery, antihistamine, renal insufficiency, liver insufficiency, COPD, heart failure (HF), thoracic, sleep  
12  
13 apnea, live alone, untreated sleep apnea, opioid naïve, and PCA basal rate. Body mass index was  
14  
15 fitted with restricted cubic splines to account for any non-linear relationship with the outcome.<sup>27</sup> The  
16  
17 backward variable selection algorithm was implemented and risk factors significant at 0.25 level  
18  
19 ( $p < 0.25$ ) were initially retained. The final model was fitted using only previously retained variables and  
20  
21 risk factors significant at 0.10 level ( $p < 0.10$ ) were retained. The risk score was developed from  
22  
23 retained risk factors in the final model. A bootstrap approach with 1000 resamples was used to validate  
24  
25 the model, and a discriminative index calculated.<sup>28</sup>

26  
27  
28 Data analysis was conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R version  
29  
30 3.5.0 (The R Foundation for Statistical Computing) statistical programs.

### 31 32 33 34 Patient and Public Involvement:

35  
36  
37 There was no patient or public involvement in setting the research question or the outcome  
38  
39 measures, in the design and implementation of the study, or dissemination of results.

## 40 41 42 43 **RESULTS**

44  
45 Between July 2016 and June 2018, a total of 163,190 unique inpatient hospitalizations had  
46  
47 documentation of opioid administration. Naloxone was found to have been administered in 961 cases.  
48  
49 As shown in Figure 1, following exclusion of patients who received naloxone during procedural  
50  
51 sedation, to treat a pre-admission overdose, or for an indication other than oversedation, we identified  
52  
53 293 (0.18%) hospitalizations with opioid administration that resulted in oversedation.

1  
2  
3 Table 1 compares patients characteristics between oversedated and non oversedated groups.  
4  
5 Bivariate analysis showed significant differences existed for most of the characteristics, except sex,  
6  
7 race, ethnicity, average BMI, and having a thoracic or large incision that interferes with adequate  
8  
9 ventilation. In the multivariable model, age, sex, BMI, COPD, concurrent administration of sedating  
10  
11 medication, renal insufficiency, liver insufficiency, opioid naivety, sleep apnea, and surgery were  
12  
13 significantly associated with risk of oversedation (Table 2). The strongest predictor of oversedation was  
14  
15 concurrent administration of another medication with sedative properties (adjusted hazard ratio, 95%CI  
16  
17 = 3.88, 2.48-6.06); Table 3 shows the medication types most frequently implicated. Older age was also  
18  
19 significantly associated with increased risk of oversedation: patients' aged 60 years were more than 1.5  
20  
21 times higher likely to be oversedated when compared to those < 50 years. BMI exhibited a non-linear  
22  
23 relationship with the outcome, with low decreasing BMI (< 20) and high increasing BMI (>35) both  
24  
25 associated with significant increase in risk of oversedation. (Figure 2). Opioid naivety had a protective  
26  
27 effect against oversedation.  
28  
29

30  
31 Table 4 presents the points scores for risk factors in the final model. Point scores ranged from 0  
32  
33 to 10 while total risk score points ranged from 0 to 24. The predictive ability of the final model was very  
34  
35 good with c-statistic = 0.755.  
36  
37

## 38 DISCUSSION

39  
40 In this study of 163,191 hospitalized patients receiving opioids, we observed an incidence of  
41  
42 oversedation of 0.18%. The strongest predictor of oversedation was concurrent administration of other  
43  
44 medications with sedative properties. Other strong predictors included older age, female sex, BMI,  
45  
46 COPD, liver insufficiency, renal insufficiency, undergoing surgery, and a history of sleep apnea or  
47  
48 positive sleep apnea screen. Opioid naivety was protective against oversedation in our population. The  
49  
50 predictive model developed showed good performance and was used to develop a points-based risk  
51  
52 score, the Oversedation Risk Criteria (ORC) that can quickly inform clinicians regarding a patient's level  
53  
54 of risk for oversedation.  
55  
56  
57

Several of the predictors identified have good face validity for increasing risk for oversedation or respiratory distress. For example, COPD, in which the respiratory system is already compromised, and liver and renal insufficiency, in which clearance of some opioids or their metabolites may be reduced, increasing drug bioavailability to unsafe levels at dosages and frequencies that would be safe in the absence of dysfunction.<sup>29 30</sup> Likewise, concurrent use of other medications with sedating effects makes intuitive sense, as it complicates the balance of cumulative sedation against management of the pain, nausea, or other symptoms each drug is prescribed to address. In the outpatient setting, co-administration of sedating agents has been shown to increase risk for overdose.<sup>31</sup> Increasing age, presence of sleep apnea, and undergoing surgery, have all been previously identified as risk factors in the literature.<sup>17</sup> In the case of age, physiological changes occur with aging that affect how medicines are handled, including alterations in volumes of drug distribution, metabolism and clearance which can prolong half-life, increasing potential for drug toxicity and the likelihood of adverse drug reactions.<sup>32</sup> Possible mechanisms that have been proposed for the impact of surgery include a combination of the residual effects of anaesthetic medications, as the risk appears to be greatest during the first 12 to 24 hours following surgery.<sup>17</sup> With respect to sleep apnea, it is a prevalent characteristic among patients who die due to critical respiratory events during the first 24 hours following surgery,<sup>18</sup> and among patients who suffer postoperative OIRD.<sup>1</sup> The intermittent hypoxia that is a component of obstructive sleep apnea has been shown to both increase pain and enhance opioid effects; in addition, opioids attenuate the arousal response to hypoxia and prolong airway obstruction, a combination of effects that has been hypothesized as explaining the association between sleep apnea and risk for OIRD.<sup>17 33</sup> Our findings regarding the risk associated with BMI are unique in that, while previous studies have found increased risk of oversedation or OIRD with obesity,<sup>12</sup> ours is the first to elucidate the J-shaped curve in which risk increases as BMI values move away in either direction from the point of inversion at 26 kg.m<sup>2</sup> – although a similar relationship between BMI and risk for adverse outcomes has been shown in other contexts.<sup>27</sup>

1  
2  
3 The low incidence of oversedation observed here was in line with previous reports examining  
4 similarly severe opioid-related adverse events (ie, necessitating the administration of a reversal agent  
5 such as naloxone). The frequency of such events varies according to the population studied – for  
6 example, reported at 0.4% in hospitalized medical patients receiving opioids,<sup>24</sup> 0.1% for postoperative  
7 patients,<sup>34</sup> 0.3% for patients undergoing major surgery,<sup>35</sup> and  $\leq 0.07\%$  in women who had undergone  
8 caesarean.<sup>36</sup> Previous studies have also set out to develop risk prediction models for OIRD or  
9 oversedation. These include a small case-control study from a US community hospital considering all  
10 hospitalized patients receiving opioids,<sup>16</sup> a large observational study of medical patients hospitalized in  
11 the United States receiving opioids,<sup>24</sup> and a risk score developed from an international prospective trial  
12 (PRODIGY) of the use of continuous capnography and oximetry to monitor patients receiving opioids  
13 on general inpatient wards.<sup>22</sup> One additional case-control study by Pawasaukas et al<sup>37</sup> did not develop  
14 a risk model *per se*, but identified a set of risk factors and found that patients with a higher number of  
15 these factors were more likely to experience oversedation. Predictors included in these previous  
16 models both overlapped with and differed from the predictors used in our risk score. Older age was  
17 consistently identified as a risk factor, and some measure related to sleep apnea was included as a risk  
18 factor (sleep disorders,<sup>22</sup> untreated sleep apnea,<sup>16</sup> or obstructive sleep apnea<sup>24</sup>) in all but Pawasaukas  
19 et al.<sup>37</sup> Two of the previous risk models, as well as Pawasaukas et al,<sup>37</sup> included factors related to the  
20 renal insufficiency variable in our risk model (comorbid renal disease<sup>16</sup> and renal failure on  
21 admission<sup>24</sup>), but only Pawasaukas et al<sup>37</sup> (hepatic disease) and the risk model developed for medical  
22 hospitalizations (hepatic failure on admission<sup>24</sup>) included any measure similar to the liver insufficiency  
23 variable in our model. These were also the only two models to include measures related to our  
24 strongest predictor of oversedation: concurrent administration of other medications with sedative  
25 properties (concurrent sedating medications,<sup>37</sup> and short-acting benzodiazepine exposure and  
26 antipsychotic exposure<sup>24</sup>). While sex was included in all models except Pawasaukas et al<sup>37</sup>, two of the  
27 previous studies identified female sex as associated with increased risk<sup>16 24</sup> (as in our model) while the  
28 third identified male sex as being so associated.<sup>22</sup> Similarly, opioid naivety was included in the  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 PRODIGY risk score as a risk factor,<sup>22</sup> while in our model, and in Pawasaukas et al,<sup>37</sup> it was a  
4 protective characteristic. Of the remaining predictors in our model, Pawasaukas et al<sup>37</sup> was the only  
5 previous model to include BMI and respiratory disease. None of the previous models included surgery  
6 (understandable for the risk model targeting medical hospitalizations only<sup>24</sup>), or PCA basal rate  
7 (although one did identify receipt of long-acting oxycodone or as-needed hydromorphone as a risk  
8 factor, which is physiologically similar).<sup>16</sup> Risk factors they identified and included that were not a part of  
9 our model include congestive heart failure,<sup>22,24</sup> psychosis or depression,<sup>24</sup> opioid abuse/dependence,<sup>24</sup>  
10 non-opioid drug abuse/dependence,<sup>24</sup> and presence on admission of respiratory failure,  
11 shock/hypotension on admission, acidosis, or neurologic failure.<sup>24</sup> Despite these differences, the  
12 performance of our risk model and the previous models is similar: both the PRODIGY model reported  
13 and the risk model targeting medical hospitalized patients reported c-statistics of 0.68-0.71,<sup>22,24</sup> which  
14 our model modestly out-performed at 0.755, while the remaining risk model, which was developed from  
15 a small single center study, achieved a c-statistic of 0.86.<sup>16</sup> The PRODIGY score showed greater  
16 separation in risk for OIRD between its low, medium, and high risk score categories (24%, 42%, and  
17 65%<sup>22</sup> compared to our <5%, 5-15%, and >15%), but this is likely explained by their having examined  
18 respiratory depression detected by continuous pulse oximetry and capnography monitoring, rather than  
19 the clinically relevant potentially life-threatening events requiring naloxone reversal we examined.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Some limitations should be kept in mind when interpreting our results. First, while our study  
41 sample was large and drawn from 12 acute care hospitals, it was nonetheless drawn from a single  
42 health care system. To the extent that risk for oversedation is affected by institutional prescribing  
43 policies or clinical decision support tools, monitoring schedules/equipment/staffing resources, and  
44 similar structural considerations governed at the health care system level, our findings may be less  
45 generalizable to all other settings. The differences noted in the risk factors included among the risk  
46 scores that have been developed to date – with all models showing good discrimination – indicates that  
47 there is further work to be done explain these discrepancies. Second, as was noted by the developers  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 of a previous risk score focusing on oversedation or OIRD events identified through naloxone  
4 reversal,<sup>24</sup> the rarity of this adverse outcome keeps the positive predictive value of even a risk score  
5 with good discrimination relatively low. Thus, while the risk score offers important value in terms of  
6 identifying patients at increased risk for OIRD or oversedation, care must still be taken in selecting  
7 mechanisms for mitigating that risk, to avoid issues such as alarm fatigue that have been reported as  
8 barriers to increased monitoring (human or electronic) to catch earlier signs of oversedation and  
9 prevent its progression.<sup>8</sup>

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

Recommendations included in national guidelines on monitoring for OIRD and oversedation include that “all patients who will receive opioids undergo a comprehensive assessment of level of individual risk before initiation of opioid therapy.”<sup>10</sup> While the guidelines go on to suggest that a risk factor checklist be integrated into the electronic health record to assist with this comprehensive assessment and its documentation, no guidance is provided on how clinicians should judge cumulative risk for patients in whom multiple risk factors are present. The ORC risk score we have developed is a tool to achieve this, and unlike previous studies, is applicable to all adult patients admitted to an acute care hospital. Future research should include evaluation of the ORC risk score for use in ambulatory centers: as more procedures that have traditionally been performed in the high resource setting of acute care hospitals transition to such settings,<sup>38</sup> where the availability of staff and resources to monitor patients for or respond to events of OIRD or oversedation may be more limited, identification of high-risk patients may be even more critical for maintaining patient safety.

Beyond application to targeted monitoring of high-risk patients for early detection of and intervention to prevent progression of OIRD and oversedation events, our results suggest opportunities for prevention through interventions aimed at prescribing clinicians – for example, clinical decision support utilizing the ORC offered when concurrent prescriptions for opioids and other sedating medications are entered. Such preventive approaches will be critical to achieving sustained improvement, as the high rate of false positive alarms – even among patients at high risk for OIRD and



oversedation – leave strategies that focus exclusively on monitoring and early detection vulnerable to alarm fatigue and competing priorities for attention among staff tasked with responding.

### **Funding:**

This work was funded by the Baylor Health Care System Foundation. The funder played no role in this study, and the research team operated independently.

### **Contributions of the authors:**

Garrett (study guarantor): study concept, study design, data analysis, data interpretation, drafting the manuscript

Vanston: data collection, data management, revising the manuscript

da Graca: literature search, drafting the manuscript

Ogola: data collection, data analysis, figures and tables, drafting the manuscript

Kouznetsova: study concept, revising the manuscript

Cassity: data collection, revising the manuscript

Hall: data collection, data management, revising the manuscript

Qui: data collection, data management, revising the manuscript

**Transparency declaration:** I, Dr. John Garrett, affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned) have been explained.

**Data sharing:** Please contact the corresponding author with any requests.

**Conflicts of interest:** The authors have no conflicts of interest to declare.

## REFERENCES

1. Lee LA, Caplan RA, Stephens LS, et al. Postoperative opioid-induced respiratory depression: a closed claims analysis. *Anesthesiology* 2015;122(3):659-65. doi: 10.1097/ALN.0000000000000564 [published Online First: 2014/12/24]
2. The Joint Commission. Safe use of opioids in hospitals. *Sentinel Event Alert* 2012;49:1-5.
3. Jarzyna D, Jungquist CR, Pasero C, et al. American Society for Pain Management Nursing guidelines on monitoring for opioid-induced sedation and respiratory depression. *Pain Manag Nurs* 2011;12(3):118-45 e10. doi: 10.1016/j.pmn.2011.06.008 [published Online First: 2011/09/07]
4. Herzig SJ, Rothberg MB, Cheung M, et al. Opioid utilization and opioid-related adverse events in nonsurgical patients in US hospitals. *J Hosp Med* 2014;9(2):73-81. doi: 10.1002/jhm.2102 [published Online First: 2013/11/15]
5. Kessler ER, Shah M, Gruschkus SK, et al. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. *Pharmacotherapy* 2013;33(4):383-91. doi: 10.1002/phar.1223 [published Online First: 2013/04/05]
6. Minkowitz HS, Gruschkus SK, Shah M, et al. Adverse drug events among patients receiving postsurgical opioids in a large health system: risk factors and outcomes. *Am J Health Syst Pharm* 2014;71(18):1556-65. doi: 10.2146/ajhp130031 [published Online First: 2014/09/01]
7. Gupta RA, Edwards DA. Monitoring for opioid-induced respiratory depression. *APSF News* 2018;32:70-72.
8. Jungquist CR, Willens JS, Dunwoody DR, et al. Monitoring for opioid-induced advancing sedation and respiratory depression: ASPMN membership survey of current practice. *Pain Manag Nurs* 2014;15(3):682-93. doi: 10.1016/j.pmn.2013.12.001 [published Online First: 2014/03/25]

- 1  
2  
3 9. Practice Guidelines for the Prevention, Detection, and Management of Respiratory Depression  
4  
5 Associated with Neuraxial Opioid Administration: An Updated Report by the American Society of  
6  
7 Anesthesiologists Task Force on Neuraxial Opioids and the American Society of Regional  
8  
9 Anesthesia and Pain Medicine. *Anesthesiology* 2016;124(3):535-52. doi:  
10  
11 10.1097/ALN.0000000000000975 [published Online First: 2015/12/15]  
12  
13  
14 10. Jungquist CR, Quinlan-Colwell A, Vallerand A, et al. American Society for Pain Management  
15  
16 Nursing Guidelines on Monitoring for Opioid-Induced Advancing Sedation and Respiratory  
17  
18 Depression: Revisions. *Pain Manag Nurs* 2020;21(1):7-25. doi: 10.1016/j.pmn.2019.06.007  
19  
20 [published Online First: 2019/08/05]  
21  
22 11. The Joint Commission. Joint Commission Enhances Pain Assessment and Management  
23  
24 Requirements for Accredited Hospitals. *The Joint Commission Perspectives* 2017;37(7):2-4.  
25  
26  
27 12. Gupta K, Prasad A, Nagappa M, et al. Risk factors for opioid-induced respiratory depression and  
28  
29 failure to rescue: a review. *Curr Opin Anaesthesiol* 2018;31(1):110-19. doi:  
30  
31 10.1097/ACO.0000000000000541 [published Online First: 2017/11/10]  
32  
33  
34 13. Gordon DB, Pellino TA. Incidence and characteristics of naloxone use in postoperative pain  
35  
36 management: a critical examination of naloxone use as a potential quality measure. *Pain Manag*  
37  
38 *Nurs* 2005;6(1):30-6. doi: 10.1016/j.pmn.2004.12.003 [published Online First: 2005/05/27]  
39  
40  
41 14. Overdyk FJ, Carter R, Maddox RR, et al. Continuous oximetry/capnometry monitoring reveals  
42  
43 frequent desaturation and bradypnea during patient-controlled analgesia. *Anesth Analg*  
44  
45 2007;105(2):412-8. doi: 10.1213/01.ane.0000269489.26048.63 [published Online First:  
46  
47 2007/07/25]  
48  
49 15. Overdyk F, Dahan A, Roozkrans M, et al. Opioid-induced respiratory depression in the acute care  
50  
51 setting: a compendium of case reports. *Pain Manag* 2014;4(4):317-25. doi: 10.2217/pmt.14.19  
52  
53 [published Online First: 2014/10/11]  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 16. Brant JM, Stringer L, Jurkovich LR, et al. Predictors of oversedation in hospitalized patients. *Am J*  
4 *Health Syst Pharm* 2018;75(18):1378-85. doi: 10.2146/ajhp170558 [published Online First:  
5 2018/09/08]  
6  
7  
8  
9  
10 17. Gupta K, Nagappa M, Prasad A, et al. Risk factors for opioid-induced respiratory depression in  
11 surgical patients: a systematic review and meta-analyses. *BMJ Open* 2018;8(12):e024086. doi:  
12 10.1136/bmjopen-2018-024086 [published Online First: 2018/12/16]  
13  
14  
15  
16 18. Ramachandran SK, Haider N, Saran KA, et al. Life-threatening critical respiratory events: a  
17 retrospective study of postoperative patients found unresponsive during analgesic therapy. *J*  
18 *Clin Anesth* 2011;23(3):207-13. doi: 10.1016/j.jclinane.2010.09.003 [published Online First:  
19 2011/05/17]  
20  
21  
22  
23  
24 19. Weingarten TN, Herasevich V, McGlinch MC, et al. Predictors of Delayed Postoperative Respiratory  
25 Depression Assessed from Naloxone Administration. *Anesth Analg* 2015;121(2):422-9. doi:  
26 10.1213/ANE.0000000000000792 [published Online First: 2015/05/21]  
27  
28  
29  
30  
31 20. Weingarten TN, Chong EY, Schroeder DR, et al. Predictors and outcomes following naloxone  
32 administration during Phase I anesthesia recovery. *J Anesth* 2016;30(1):116-22. doi:  
33 10.1007/s00540-015-2082-0 [published Online First: 2015/10/10]  
34  
35  
36  
37 21. Overdyk FJ, Dowling O, Marino J, et al. Association of Opioids and Sedatives with Increased Risk  
38 of In-Hospital Cardiopulmonary Arrest from an Administrative Database. *PLoS One*  
39 2016;11(2):e0150214. doi: 10.1371/journal.pone.0150214 [published Online First: 2016/02/26]  
40  
41  
42  
43 22. Khanna AK, Bergese SD, Jungquist CR, et al. Prediction of Opioid-Induced Respiratory Depression  
44 on Inpatient Wards Using Continuous Capnography and Oximetry: An International Prospective,  
45 Observational Trial. *Anesth Analg* 2020;131(4):1012-24. doi: 10.1213/ANE.0000000000004788  
46  
47  
48  
49 [published Online First: 2020/09/15]  
50  
51  
52 23. Khanna AK, Overdyk FJ, Greening C, et al. Respiratory depression in low acuity hospital settings-  
53 Seeking answers from the PRODIGY trial. *J Crit Care* 2018;47:80-87. doi:  
54 10.1016/j.jcrc.2018.06.014 [published Online First: 2018/06/25]  
55  
56  
57  
58  
59  
60

- 1  
2  
3 24. Herzig SJ, Stefan MS, Pekow PS, et al. Risk Factors for Severe Opioid-Related Adverse Events in  
4 a National Cohort of Medical Hospitalizations. *J Gen Intern Med* 2020;35(2):538-45. doi:  
5 10.1007/s11606-019-05490-w [published Online First: 2019/11/16]  
6  
7  
8  
9 25. Zedler B, Xie L, Wang L, et al. Development of a Risk Index for Serious Prescription Opioid-Induced  
10 Respiratory Depression or Overdose in Veterans' Health Administration Patients. *Pain Med*  
11 2015;16(8):1566-79. doi: 10.1111/pme.12777 [published Online First: 2015/06/17]  
12  
13  
14  
15 26. Zedler BK, Saunders WB, Joyce AR, et al. Validation of a Screening Risk Index for Serious  
16 Prescription Opioid-Induced Respiratory Depression or Overdose in a US Commercial Health  
17 Plan Claims Database. *Pain Med* 2018;19(1):68-78. doi: 10.1093/pm/pnx009 [published Online  
18 First: 2017/03/25]  
19  
20  
21  
22  
23 27. Filardo G, Hamilton C, Hamman B, et al. Categorizing BMI may lead to biased results in studies  
24 investigating in-hospital mortality after isolated CABG. *J Clin Epidemiol* 2007;60(11):1132-9. doi:  
25 10.1016/j.jclinepi.2007.01.008 [published Online First: 2007/10/17]  
26  
27  
28  
29 28. Harrell FE. Regression Modeling Strategies: With applications to Linear Models, Logistic  
30 Regression and Survival Analysis. New York: Springer-Verlag 2001.  
31  
32  
33 29. Bosilkovska M, Walder B, Besson M, et al. Analgesics in patients with hepatic impairment:  
34 pharmacology and clinical implications. *Drugs* 2012;72(12):1645-69. doi: 10.2165/11635500-  
35 000000000-00000 [published Online First: 2012/08/08]  
36  
37  
38  
39 30. Dean M. Opioids in renal failure and dialysis patients. *J Pain Symptom Manage* 2004;28(5):497-  
40 504. doi: 10.1016/j.jpainsymman.2004.02.021 [published Online First: 2004/10/27]  
41  
42  
43 31. Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids  
44 and benzodiazepines and overdose: retrospective analysis. *BMJ* 2017;356:j760. doi:  
45 10.1136/bmj.j760 [published Online First: 2017/03/16]  
46  
47  
48  
49 32. Davies EA, O'Mahony MS. Adverse drug reactions in special populations - the elderly. *Br J Clin*  
50 *Pharmacol* 2015;80(4):796-807. doi: 10.1111/bcp.12596 [published Online First: 2015/01/27]  
51  
52  
53  
54  
55  
56  
57

- 1  
2  
3 33. Lam KK, Kunder S, Wong J, et al. Obstructive sleep apnea, pain, and opioids: is the riddle solved?  
4  
5 *Curr Opin Anaesthesiol* 2016;29(1):134-40. doi: 10.1097/ACO.0000000000000265 [published  
6  
7 Online First: 2015/11/07]  
8  
9  
10 34. Khelemsky Y, Kothari R, Campbell N, et al. Incidence and Demographics of Post-Operative  
11  
12 Naloxone Administration: A 13-Year Experience at a Major Tertiary Teaching Institution. *Pain*  
13  
14 *Physician* 2015;18(5):E827-9. [published Online First: 2015/10/03]  
15  
16 35. Cashman JN, Dolin SJ. Respiratory and haemodynamic effects of acute postoperative pain  
17  
18 management: evidence from published data. *Br J Anaesth* 2004;93(2):212-23. doi:  
19  
20 10.1093/bja/aeh180 [published Online First: 2004/06/01]  
21  
22 36. Crowgey TR, Dominguez JE, Peterson-Layne C, et al. A retrospective assessment of the incidence  
23  
24 of respiratory depression after neuraxial morphine administration for postcesarean delivery  
25  
26 analgesia. *Anesth Analg* 2013;117(6):1368-70. doi: 10.1213/ANE.0b013e3182a9b042  
27  
28 [published Online First: 2013/11/22]  
29  
30 37. Pawasauskas J, Stevens B, Youssef R, et al. Predictors of naloxone use for respiratory depression  
31  
32 and oversedation in hospitalized adults. *Am J Health Syst Pharm* 2014;71(9):746-50. doi:  
33  
34 10.2146/ajhp130568 [published Online First: 2014/04/16]  
35  
36  
37 38. DeCook CA. Outpatient Joint Arthroplasty: Transitioning to the Ambulatory Surgery Center. *J*  
38  
39 *Arthroplasty* 2019;34(7S):S48-S50. doi: 10.1016/j.arth.2019.01.006 [published Online First:  
40  
41 2019/02/19]  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

## 53 Figure Legends

54  
55  
56  
57

1  
2  
3 Figure 1. Inclusion and exclusion of hospital encounters for the development of the Oversedation Risk  
4  
5 Criteria (ORC) score.

6  
7 ED = emergency department; OB = Obstetric; OR = operating room  
8  
9

10  
11 Figure 2. Risk of opioid-induced respiratory depression or oversedation by body mass index (BMI)  
12  
13

14  
15 Figure 3. Risk of opioid-induced respiratory depression or oversedation by Oversedation Risk Criteria  
16  
17 (ORC) score.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## TABLES

**Table 1.** Patient demographic and clinical characteristics and outcomes for inpatients who did vs did not experience an opioid-related oversedation event

	Oversedation (N=293)	No Oversedation (N=162,897)	P-value
Age (years)			< 0.001
<50	52 (17.7%)	63361 (38.9%)	
50-59	54 (18.4%)	26319 (16.2%)	
60-69	74 (25.3%)	31329 (19.2%)	
70+	113 (38.6%)	41888 (25.7%)	
Sex (Female)	191 (65.2%)	99562 (61.1%)	0.154
Race			0.618
White	230 (78.5%)	124351 (76.3%)	
Black	46 (15.7%)	29139 (17.9%)	
Other	17 (5.8%)	9407 (5.8%)	
Hispanic ethnicity	34 (11.6%)	25330 (15.5%)	0.063
BMI - Mean $\pm$ SD (kg.m <sup>2</sup> )	30.1 $\pm$ 10.3	30.0 $\pm$ 8.2	0.745
Concurrent administration of sedating medication	267 (91.1%)	95495 (58.6%)	< 0.001
Antihistamine	73 (24.9%)	29952 (18.4%)	0.004
Renal Insufficiency diagnosis	141 (48.1%)	46415 (28.5%)	< 0.001
Liver Insufficiency diagnosis	189 (64.5%)	67917 (41.7%)	< 0.001
Chronic obstructive pulmonary disease	73 (24.9%)	20592 (12.6%)	< 0.001
Heart failure	72 (24.6%)	25506 (15.7%)	< 0.001
Thoracic or large incision that interferes with adequate ventilation	20 (6.8%)	8577 (5.3%)	0.232
Positive sleep apnea screen: Snore	95 (32.9%)	40018 (24.9%)	< 0.001
Positive sleep apnea screen: Doze off	76 (26.3%)	22167 (13.8%)	< 0.001
Live alone	4 (1.4%)	603 (0.4%)	0.018
Smoking History			0.014
Non-Smoker	152 (51.9%)	95410 (58.6%)	
Former Smoker	90 (30.7%)	38785 (23.8%)	
Current Smoker	40 (13.7%)	24733 (15.2%)	
Unknown/Missing	11 (3.8%)	3969 (2.4%)	
Surgery	148 (50.5%)	55262 (33.9%)	< 0.001
Untreated obstructive sleep apnea	55 (19.4%)	18846 (12.0%)	< 0.001
Opioid Naive	155 (52.9%)	105519 (64.8%)	< 0.001
PCA basal	7 (2.4%)	1066 (0.7%)	< 0.001
Days on opioids - Median (Q1, Q3)	7.0 (4.0, 13.0)	3.0 (2.0, 5.0)	< 0.001
Disposition			< 0.001
Expired	20 (6.8%)	4743 (2.9%)	
Home	140 (47.8%)	128709 (79.0%)	
Transferred to other facilities	133 (45.4%)	29445 (18.1%)	
Length of Stay (days) - Median (Q1, Q3)	9.0 (5.0, 15.0)	3.0 (2.0, 6.0)	< 0.001

BMI – body mass index; SD – standard deviation; Q - quartile



**Table 2.** Associations between risk factors included in the full and reduced models for predicting opioid-induced respiratory depression or oversedation.


Risk factors	HR (95%CI) and P-value	
	Full Model	Reduced Model
Age (years)		
50-59	1.39 (0.91 - 2.13) p = 0.13	1.39 (0.91 - 2.12) p = 0.13
60-69	1.52 (1.01 - 2.28) p = 0.04	1.54 (1.03 - 2.30) p = 0.03
70+	1.69 (1.13 - 2.52) p = 0.01	1.75 (1.19 - 2.57) p = <.01
Sex (Female vs. Male)	1.59 (1.21 - 2.09) p = <.01	1.60 (1.23 - 2.09) p = <.01
Race		
Black vs White	0.83 (0.57 - 1.20) p = 0.31	
Other vs White	1.21 (0.70 - 2.10) p = 0.49	
Hispanic ethnicity	1.06 (0.71 - 1.58) p = 0.78	
Smoking History		
Former vs Never	1.03 (0.77 - 1.38) p = 0.84	
Current vs Never	0.86 (0.58 - 1.28) p = 0.47	
BMI (kg/m <sup>2</sup> )		
(BMI<26)	1.02 (1.00 - 1.03) p = 0.07	1.02 (1.00 - 1.04) p = 0.05
(BMI >= 26)	0.68 (0.48 - 0.96) p = 0.03	0.69 (0.49 - 0.97) p = 0.03
Antihistamine	0.91 (0.68 - 1.22) p = 0.53	
Chronic obstructive pulmonary disease	1.57 (1.14 - 2.15) p = <.01	1.48 (1.10 - 1.99) p = <.01
Concurrent administration of sedating medication	3.89 (2.48 - 6.10) p = <.01	3.88 (2.48 - 6.06) p = <.01
Heart Failure	0.89 (0.64 - 1.22) p = 0.47	
Live alone	2.55 (0.63 - 10.29) p = 0.19	
Liver insufficiency diagnosis	1.60 (1.21 - 2.10) p = <.01	1.62 (1.23 - 2.12) p = <.01
Opioid Naive	0.76 (0.59 - 0.97) p = 0.03	0.74 (0.58 - 0.95) p = 0.02
PCA Basal	1.87 (0.82 - 4.26) p = 0.13	1.96 (0.87 - 4.46), p = 0.10
Renal insufficiency	1.40 (1.07 - 1.85) p = 0.02	1.35 (1.03 - 1.76) p = 0.03
Positive sleep apnea screen (Snore or Doze-off)	1.42 (1.08 - 1.87) p = 0.01	1.45 (1.11 - 1.88) p = <.01
Surgery	1.57 (1.20 - 2.04) p = <.01	1.53 (1.18 - 1.98) p = <.01
Thoracic or large incision that interferes with adequate ventilation	0.68 (0.41 - 1.12) p = 0.13	
Untreated obstructive sleep apnea	1.18 (0.84 - 1.66) p = 0.34	
BMI – body mass index; CI – confidence interval; HR – hazard ratio		

**Table 3. Medications with sedating properties prescribed concomitantly with opioids in patients who experienced an opioid-related oversedation event**

Drug type/category	n (%)
Benzodiazepine	245 (29.0)
Antidepressants	186 (22.0)
Gamma-aminobutyric acid analog	124 (14.7)
Miscellaneous anxiolytic, sedative and hypnotic (sleep aids)	86 (10.2)
Antipsychotic	69 (8.2)
Antihistamine	68 (8.0)
Anticonvulsant	38 (4.5)
Dopaminergic anti-Parkinsonism agents	15 (1.8)
Barbiturate	6 (0.7)
Phenothiazine antiemetics	5 (0.6)
Carbonic anhydrase inhibitor	3 (0.4)

**Table 4. Points assigned per risk factor in the Oversedation Risk Criteria (ORC) score**


Risk factor	Points
Age (years)	
< 50	0
50-59	1
60+	2
Sex - Female	2
BMI (kg/m <sup>2</sup> )	
10	5
20	2
30	0
40	1
50	2
60	3
70	4
80	5
90	6
100	7
110	8
120	9
130	10
Concurrent administration of sedating medication	5
Renal Insufficiency	1
Liver Insufficiency	2
Chronic obstructive pulmonary disease	1
Sleep Apnea	2
Surgery within 24 hours	2
Not Opioid Naive	1
PCA Basal	3
BMI – body mass index	



Inclusion and exclusion of hospital encounters for the development of the Oversedation Risk Criteria (ORC) score.


91x85mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Risk of opioid-induced respiratory depression or oversedation by body mass index (BMI)

56x57mm (300 x 300 DPI)



Risk of Oversedation	ORC Score
>20% (high risk)	22-24
11-20% (moderate risk)	18-21
0-10% (low risk)	< 18

Risk of opioid-induced respiratory depression or oversedation by Oversedation Risk Criteria (ORC) score.

56x53mm (300 x 300 DPI)

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7-8
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8
Bias	9	Describe any efforts to address potential sources of bias	8-9
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	8-9
		(c) Explain how missing data were addressed	23
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	n/a

Continued on next page

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	27, Fig 1
		(b) Give reasons for non-participation at each stage	Fig 1
		(c) Consider use of a flow diagram	Fig 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	n/a
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	Tables 1
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2
		(b) Report category boundaries when continuous variables were categorized	Table 2
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



# BMJ Open

## Predicting Opioid Induced Oversedation in Hospitalized Patients: A Multicenter Observational Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-051663.R1
Article Type:	Original research
Date Submitted by the Author:	31-Aug-2021
Complete List of Authors:	Garrett, John; Baylor University Medical Center at Dallas, Department of Emergency Medicine Vanston , Anneliese ; Baylor University Medical Center at Dallas Ogola, Gerald; Baylor Scott & White Research Institute da Graca, Briget; Baylor Scott & White Research Institute, Cassity, Cindy; Baylor University Medical Center at Dallas Kouznetsova, Maria; Baylor Scott & White Health Hall, Lauren R.; Baylor Scott & White Health Qiu, Taoran; Baylor Scott & White Health
<b>Primary Subject Heading</b>:	Pharmacology and therapeutics
Secondary Subject Heading:	Epidemiology, Anaesthesia, Health services research
Keywords:	Pain management < ANAESTHETICS, Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Title:** Predicting Opioid Induced Oversedation in Hospitalized Patients: A Multicenter Observational  
4 Study  
5  
6  
7

8 **Authors:**

9  
10 John S. Garrett MD MRA FACEP  
11 Chair, Department of Emergency Medicine, Baylor University Medical Center  
12 [John.garrett@bswhealth.org](mailto:John.garrett@bswhealth.org)  
13 ORCID ID: 0000-0002-0012-7285  
14

15 Anneliese Vanston BS RN  
16 Patient Safety Coordinator, Baylor University Medical Center  
17 [apvanston@gmail.com](mailto:apvanston@gmail.com)  
18

19 Gerald Ogola PhD  
20 Biostatistician, Baylor Scott & White Research Institute  
21 [Gerald.ogola@bswhealth.org](mailto:Gerald.ogola@bswhealth.org)  
22

23  
24 Briget da Graca, JD, MS  
25 Assistant Investigator, Baylor Scott & White Research Institute  
26 [Briget.dagraca@bswhealth.org](mailto:Briget.dagraca@bswhealth.org)  
27

28  
29 Cindy Cassity MSN RN  
30 Director, Patient Safety and Value-Based Healthcare Improvement, Baylor University Medical Center  
31 [Cindy.cassity@bswhealth.org](mailto:Cindy.cassity@bswhealth.org)  
32

33 Maria A Kouznetsova, MS, MPH, PhD  
34 Analytics Developer II, Baylor Scott & White Health  
35 [maria\\_kuznetsova@yahoo.com](mailto:maria_kuznetsova@yahoo.com)  
36

37 Lauren R. Hall, PhD, MPH  
38 Analytics Developer II, Baylor Scott & White Health  
39 [lauren.hall1@bswhealth.org](mailto:lauren.hall1@bswhealth.org)  
40

41  
42 Taoran Qiu, MS  
43 Analytics Developer II, Baylor Scott & White Health  
44 [taoran.qiu@bswhealth.org](mailto:taoran.qiu@bswhealth.org)  
45  
46  
47

48 Correspondence to:

49  
50 John S. Garrett MD MRA FACEP  
51 Chair Department of Emergency Medicine  
52 Baylor University Medical Center  
53 3500 Gaston Avenue  
54 Dallas, Texas 75246  
55 Phone: 214-820-8646  
56  
57

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Email: [john.garrett@bswhealth.org](mailto:john.garrett@bswhealth.org)  
<https://orcid.org/0000-0002-0012-7285>

Word count: Abstract – 300; Text – 3547  
Tables – 4  
Figures – 3  
References - 38

For peer review only

**ABSTRACT (300 words)**

Objectives: Opioid-induced respiratory depression (OIRD) and oversedation are rare but potentially devastating adverse events in hospitalized patients. We investigated which features predict an individual patient's risk of OIRD or oversedation; and developed a risk stratification tool that can be used to aid point-of-care clinical decision-making.

Design: Retrospective observational study

Setting: Twelve acute care hospitals in a large not-for-profit integrated delivery system

Participants: All inpatients  $\geq 18$  years admitted between July 1, 2016 and June 30, 2018 who received an opioid during their stay (163,190 unique hospitalizations).

Main outcome measures: The primary outcome was occurrence of sedation or respiratory depression severe enough that emergent reversal with naloxone was required, as determined from medical record review; if naloxone reversal was unsuccessful or if there was no evidence of hypoxic encephalopathy or death due to oversedation, it was not considered an oversedation event.

Results: Age, sex, body mass index, chronic obstructive pulmonary disease, concurrent sedating medication, renal insufficiency, liver insufficiency, opioid naïvety, sleep apnea, and surgery were significantly associated with risk of oversedation. The strongest predictor was concurrent administration of another sedating medication (adjusted hazard ratio, 95%CI = 3.88, 2.48-6.06); the most common such medications were benzodiazepines (29%), antidepressants (22%), and gamma-aminobutyric acid analog (14.7%). The c-statistic for the final model was 0.755. The 24-point Oversedation Risk Criteria (ORC) score developed from the model stratifies patients as high (>20%,  $\geq 21$  points), moderate (11-20%, 10-20 points), and low risk ( $\leq 10\%$ , <10 points).

Conclusions: The ORC risk score identifies patients at high risk for OIRD or oversedation from routinely collected data, enabling targeted monitoring for early detection and intervention. It can also be applied to preventive strategies – for example, clinical decision support offered when concurrent prescriptions for opioids and other sedating medications are entered that shows how the chosen combination impacts the patient's risk.

1  
2  
3 Keywords: oversedation, opioid-induced respiratory distress, risk score  
4  
5  
6

### 7 **Strengths and limitations of this study**

- 8 • This multi-hospital study is the first large study to develop a risk score for oversedation/opioid-  
9 induced respiratory depression that is applicable to all adult hospitalized patients prescribed  
10 opioids.  
11  
12
- 13 • All predictors used to build the novel 24-point Oversedation Risk Criteria (ORC) score presented  
14 here are routinely collected and readily available from the electronic medical record; thus,  
15 implementation will not add to clinicians' data collection burden.  
16  
17
- 18 • The predictors include both patient characteristics that cannot be modified and treatment  
19 choices that can; it can therefore both facilitate targeted monitoring for early detection and  
20 intervention on oversedation/opioid-induced respiratory distress events, and be used in clinical  
21 decision support tools, providing information regarding the impact of concomitant medication  
22 choice on a patient's risk for such an event.  
23  
24
- 25 • This is a novel risk score that should be validated in other, external case series.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

## INTRODUCTION

Opioid-induced respiratory depression (OIRD) and oversedation are rare but frequently devastating side effects of opioid analgesia in hospitalized patients. In an analysis of closed malpractice claims, more than half the OIRD events resulted in death, and another 22% in severe brain damage.<sup>1</sup> Furthermore, such events are highly preventable with improved monitoring and response.<sup>1,2</sup> The challenge, however, lies in ensuring appropriate monitoring is provided. Opioid analgesia is the primary pharmacologic intervention for managing pain in hospitalized patients,<sup>3</sup> and more than half of all non-surgical patients admitted to hospitals,<sup>4</sup> and almost all patients who undergo surgery,<sup>5,6</sup> receive opioids during their stay. At these large volumes, continuous monitoring of all patients receiving opioids is not feasible: even if hospitals were to invest in the equipment necessary to provide pulse oximetry and capnography electronic monitoring<sup>7</sup> for all patients receiving opioids, issues related to alarm fatigue and staff burden<sup>8</sup> would remain significant barriers to effective monitoring.

Acknowledging the challenges to continuously monitoring all patients receiving opioids, clinical practice guidelines (for example, from the American Society of Anesthesiologists<sup>9</sup> and the American Society for Pain Management Nursing<sup>10</sup>), as well as the Joint Commission accreditation requirements addressing safe use of opioids for pain management,<sup>11</sup> include the step of identifying patients at high risk of OIRD or oversedation for enhanced monitoring. However, there is currently no agreed-upon method for assessing that risk. Multiple factors that increase patient risk – including patient demographic characteristics (such as older age<sup>12-14</sup> and female sex<sup>12,15,16</sup>), clinical characteristics (such as cardiac disease,<sup>12,17,18</sup> pulmonary disease,<sup>12,17</sup> sleep apnea,<sup>12,15-20</sup> diabetes,<sup>18,20</sup> impaired kidney function,<sup>12,15,16,18</sup> and obesity<sup>12,14,15</sup>), and opioid-related factors (higher opioid dosage,<sup>12,17,19,20</sup> route of administration<sup>12,16</sup> and concomitant use of other medications with sedative effects<sup>12,13,19,21</sup>). Survey data indicate that, while at least some of these factors are considered by most hospitals in identifying patients at high risk for OIRD and oversedation, there is substantial variation in which criteria are used.<sup>8</sup> Furthermore, simply considering the list of possible risk factors does not help clinicians quantify actual

1  
2  
3 risks for patients with multiple factors present, as it does not provide information regarding the extent to  
4  
5 which they may be additive.  
6

7 Some previous work has been done to synthesize multiple patient risk factors into clinically-  
8  
9 useful risk scores. The PRODIGY trial, for example, developed a 5-variable prediction model for OIRD,  
10  
11 using data from a prospective trial in which participants were monitored continuously via capnography  
12  
13 and pulse oximetry, but was limited to patients receiving parenteral opioids, treated on the general care  
14  
15 floor, and able to wear the continuous monitoring equipment.<sup>22 23</sup> Another risk scoring system for severe  
16  
17 opioid-related adverse events (including somnolence, respiratory depression, and cardiopulmonary  
18  
19 arrest) was developed from a US national cohort of medical hospitalizations, but did not consider  
20  
21 surgical or trauma admissions.<sup>24</sup> A risk index has also been developed and validated for serious OIRD  
22  
23 or overdose among outpatients with opioid prescriptions,<sup>25 26</sup> but has not been tested for the inpatient  
24  
25 setting (where dosages, routes of administration, and the degree of control the patient has over when  
26  
27 and how much of the medication to take, differ significantly).<sup>25 26</sup> What is thus currently missing from the  
28  
29 literature is a risk score that is applicable to all hospitalized patients. Using data from our multi-hospital  
30  
31 system, we sought to address this gap and 1) determine which features predict an individual patient's  
32  
33 risk of OIRD or oversedation; and 2) develop a risk stratification tool to determine which patients are  
34  
35 low, moderate, and high risk for OIRD or oversedation that can be used at the point-of-care to aid  
36  
37 clinical decision-making.  
38  
39  
40  
41  
42

## 43 **METHODS**

44 Study population: We considered all adult ( $\geq 18$  years) patients admitted to one of the 12 [health care  
45  
46 system] acute care hospitals in north Texas between July 1, 2016 and June 30, 2018 who received an  
47  
48 opioid during their inpatient stay.  
49  
50  
51

52  
53 Outcomes: The outcome of interest ("oversedation") was defined as an occurrence of sedation or  
54  
55 respiratory depression severe enough that the primary care team felt emergent reversal with naloxone  
56  
57



1  
2  
3 was indicated. Distinction was not made between three mechanisms through which opioid-induced  
4 ventilatory impairment (OIVI) occurs: depression of the respiratory centre in the brain stem, depression  
5 of the hypothalamus leading to increased arousal thresholds and sedation, and decreased upper  
6 airway muscle tone leading to airway obstruction. Cases in which naloxone was administered were  
7 identified from the electronic medical record and individually reviewed by one of two healthcare  
8 providers via a standardized review process. Discrepancies between reviewers were discussed until  
9 both reviewers agreed with final determination. If naloxone administration successfully reversed the  
10 sedation event or opioid medication administered as part of inpatient care was determined to be the  
11 causative etiology of sedation, the case was considered an oversedation event. Cases in which  
12 reversal with naloxone was not successful or in which the patient did not have evidence of hypoxic  
13 encephalopathy or death due to oversedation were not considered to be oversedation events. Patients  
14 who received naloxone during the course of procedural sedation were excluded from this analysis.

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31 Data collection: All data were extracted from the electronic medical record. Data were collected on  
32 patient demographics, medical history, and clinical and admission characteristics considered to be  
33 potential risk factors for oversedation, as identified in national guidelines.<sup>3</sup> Patient outcomes (discharge  
34 disposition and length of stay) were also collected. All variables are listed in Table 1.

#### 35 36 37 38 39 40 41 Statistical analysis:

42  
43 Patients' demographic characteristics, medical history and outcomes were summarized for the  
44 over-sedated and not-oversedated groups. Continuous variables were summarized by mean and  
45 standard deviation or median with interquartile range, while categorical variables were summarized by  
46 frequency and percent. Differences in the characteristics were assessed by t-tests or Kruskal-Wallis  
47 tests for continuous data, and Chi-square tests for categorical data.

48  
49  
50  
51  
52  
53  
54 Cox proportional hazards regression model was developed to predict in-hospital risk of  
55 oversedation. Survival times were defined as time from hospital admission to oversedation for patients

1  
2  
3 that experienced oversedation, or time from hospital admission to discharge for patients that were  
4  
5 never oversedated during their hospital stay. To develop the risk model, we first examined a full model  
6  
7 with all potential risk factors of interest. Risk factors considered included age, sex, race, ethnicity, body  
8  
9 mass index (BMI), smoking history, indicator of concurrent administration of sedating medication  
10  
11 (defined as sedating medications administered either before or after administration of the opioid  
12  
13 medication where the time that elapsed between administration was less than the predicted timeframe  
14  
15 of the mechanism of action for the medication that was administered first), surgery, antihistamine, renal  
16  
17 insufficiency, liver insufficiency, COPD, heart failure (HF), thoracic, sleep apnea, live alone, untreated  
18  
19 sleep apnea, opioid naïve, and PCA basal rate. Body mass index was fitted with restricted cubic  
20  
21 splines to account for any non-linear relationship with the outcome.<sup>27</sup> The backward variable selection  
22  
23 algorithm was implemented and risk factors significant at 0.25 level ( $p < 0.25$ ) were initially retained. The  
24  
25 final model was fitted using only previously retained variables and risk factors significant at 0.10 level ( $p$   
26  
27  $< 0.10$ ) were retained. The final prediction model was implemented in a nomogram to develop a risk  
28  
29 score calculator for estimating probabilities of oversedation during hospitalization for each individual.  
30  
31 Predictive performance of the nomogram was validated for discrimination and calibration on the original  
32  
33 data using 1000 bootstrap resamples. Discrimination was assessed by bootstrap-adjusted Harrell's  
34  
35 concordance index (C-index) with 95% confidence intervals.<sup>28</sup> Nomogram was developed using rms  
36  
37 package of R version 3.5.0. Distribution of the relationship between probabilities of oversedation and  
38  
39 risk scores were assessed and stratified as high, moderate and low risk.  
40  
41  
42

43 Data analysis was conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R version  
44  
45 3.5.0 (The R Foundation for Statistical Computing) statistical programs.  
46  
47  
48

#### 49 Patient and Public Involvement:

50  
51 There was no patient or public involvement in setting the research question or the outcome  
52  
53 measures, in the design and implementation of the study, or dissemination of results.  
54  
55  
56  
57

## RESULTS

Between July 2016 and June 2018, a total of 163,190 unique inpatient hospitalizations had documentation of opioid administration. Naloxone was found to have been administered in 961 cases. As shown in Figure 1, following exclusion of patients who received naloxone during procedural sedation, to treat a pre-admission overdose, or for an indication other than oversedation, we identified 293 (0.18%) hospitalizations with opioid administration that resulted in oversedation.

Table 1 compares patients characteristics between oversedated and non oversedated groups. Bivariate analysis showed significant differences existed for most of the characteristics, except sex, race, ethnicity, average BMI, and having a thoracic or large incision that interferes with adequate ventilation. In the multivariable model, age, sex, BMI, COPD, concurrent administration of sedating medication, renal insufficiency, liver insufficiency, opioid naïvety, sleep apnea, and surgery were significantly associated with risk of oversedation (Table 2). The strongest predictor of oversedation was concurrent administration of another medication with sedative properties (adjusted hazard ratio, 95%CI = 3.88, 2.48-6.06); Table 3 shows the medication types most frequently implicated. Older age was also significantly associated with increased risk of oversedation: patients' aged 60 years were more than 1.5 times higher likely to be oversedated when compared to those < 50 years. BMI exhibited a non-linear relationship with the outcome, with low decreasing BMI (< 20) and high increasing BMI (>35) both associated with significant increase in risk of oversedation. (Figure 2). Opioid naïvety had a protective effect against oversedation.

Table 4 presents the points scores for risk factors in the final model. Point scores ranged from 0 to 10 while total risk score points ranged from 0 to 24. Figure 3 shows the risk of OIRD by Oversedation Risk Criteria (ORC) score. The predictive ability of the final model was very good with c-statistic = 0.755.

## DISCUSSION

1  
2  
3 In this study of 163,191 hospitalized patients receiving opioids, we observed an incidence of  
4  
5 oversedation of 0.18%. The strongest predictor of oversedation was concurrent administration of other  
6  
7 medications with sedative properties. Other strong predictors included older age, female sex, BMI,  
8  
9 COPD, liver insufficiency, renal insufficiency, undergoing surgery, and a history of sleep apnea or  
10  
11 positive sleep apnea screen. Opioid naivety was protective against oversedation in our population. The  
12  
13 predictive model developed showed good performance and was used to develop a points-based risk  
14  
15 score, the Oversedation Risk Criteria (ORC) that can quickly inform clinicians regarding a patient's level  
16  
17 of risk for oversedation.  
18  
19

20  
21 Several of the predictors identified have good face validity for increasing risk for oversedation or  
22  
23 respiratory distress. For example, COPD, in which the respiratory system is already compromised, and  
24  
25 liver and renal insufficiency, in which clearance of some opioids or their metabolites may be reduced,  
26  
27 increasing drug bioavailability to unsafe levels at dosages and frequencies that would be safe in the  
28  
29 absence of dysfunction.<sup>29 30</sup> Likewise, concurrent use of other medications with sedating effects makes  
30  
31 intuitive sense, as it complicates the balance of cumulative sedation against management of the pain,  
32  
33 nausea, or other symptoms each drug is prescribed to address. In the outpatient setting, co-  
34  
35 administration of sedating agents has been shown to increase risk for overdose.<sup>31</sup> Increasing age,  
36  
37 presence of sleep apnea, and undergoing surgery, have all been previously identified as risk factors in  
38  
39 the literature.<sup>17</sup> In the case of age, physiological changes occur with aging that affect how medicines  
40  
41 are handled, including alterations in volumes of drug distribution, metabolism and clearance which can  
42  
43 prolong half-life, increasing potential for drug toxicity and the likelihood of adverse drug reactions.<sup>32</sup>  
44  
45 Possible mechanisms that have been proposed for the impact of surgery include a combination of the  
46  
47 residual effects of anaesthetic medications, as the risk appears to be greatest during the first 12 to 24  
48  
49 hours following surgery.<sup>17</sup> With respect to sleep apnea, it is a prevalent characteristic among patients  
50  
51 who die due to critical respiratory events during the first 24 hours following surgery,<sup>18</sup> and among  
52  
53 patients who suffer postoperative OIRD.<sup>1</sup> The intermittent hypoxia that is a component of obstructive  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 sleep apnea has been shown to both increase pain and enhance opioid effects; in addition, opioids  
4 attenuate the arousal response to hypoxia and prolong airway obstruction, a combination of effects that  
5 has been hypothesized as explaining the association between sleep apnea and risk for OIRD.<sup>17 33</sup> Our  
6 findings regarding the risk associated with BMI are unique in that, while previous studies have found  
7 increased risk of oversedation or OIRD with obesity,<sup>12</sup> ours is the first to elucidate the J-shaped curve in  
8 which risk increases as BMI values move away in either direction from the point of inversion at 26 kg.m<sup>-2</sup>  
9 – although a similar relationship between BMI and risk for adverse outcomes has been shown in other  
10 contexts.<sup>27</sup>

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21 The low incidence of oversedation observed here was in line with previous reports examining  
22 similarly severe opioid-related adverse events (ie, necessitating the administration of a reversal agent  
23 such as naloxone). The frequency of such events varies according to the population studied – for  
24 example, reported at 0.4% in hospitalized medical patients receiving opioids,<sup>24</sup> 0.1% for postoperative  
25 patients,<sup>34</sup> 0.3% for patients undergoing major surgery,<sup>35</sup> and ≤0.07% in women who had undergone  
26 caesarean.<sup>36</sup> Previous studies have also set out to develop risk prediction models for OIRD or  
27 oversedation. These include a small case-control study from a US community hospital considering all  
28 hospitalized patients receiving opioids,<sup>16</sup> a large observational study of medical patients hospitalized in  
29 the United States receiving opioids,<sup>24</sup> and a risk score developed from an international prospective trial  
30 (PRODIGY) of the use of continuous capnography and oximetry to monitor patients receiving opioids  
31 on general inpatient wards.<sup>22</sup> One additional case-control study by Pawasaukas et al<sup>37</sup> did not develop  
32 a risk model *per se*, but identified a set of risk factors and found that patients with a higher number of  
33 these factors were more likely to experience oversedation. Predictors included in these previous  
34 models both overlapped with and differed from the predictors used in our risk score. Older age was  
35 consistently identified as a risk factor, and some measure related to sleep apnea was included as a risk  
36 factor (sleep disorders,<sup>22</sup> untreated sleep apnea,<sup>16</sup> or obstructive sleep apnea<sup>24</sup>) in all but Pawasaukas  
37 et al.<sup>37</sup> Two of the previous risk models, as well as Pawasaukas et al,<sup>37</sup> included factors related to the  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 renal insufficiency variable in our risk model (comorbid renal disease<sup>16</sup> and renal failure on  
4 admission<sup>24</sup>), but only Pawasaukas et al<sup>37</sup> (hepatic disease) and the risk model developed for medical  
5 hospitalizations (hepatic failure on admission<sup>24</sup>) included any measure similar to the liver insufficiency  
6 variable in our model. These were also the only two models to include measures related to our  
7 strongest predictor of oversedation: concurrent administration of other medications with sedative  
8 properties (concurrent sedating medications,<sup>37</sup> and short-acting benzodiazepine exposure and  
9 antipsychotic exposure<sup>24</sup>). While sex was included in all models except Pawasaukas et al<sup>37</sup>, two of the  
10 previous studies identified female sex as associated with increased risk<sup>16 24</sup> (as in our model) while the  
11 third identified male sex as being so associated.<sup>22</sup> Similarly, opioid naivety was included in the  
12 PRODIGY risk score as a risk factor,<sup>22</sup> while in our model, and in Pawasaukas et al,<sup>37</sup> it was a  
13 protective characteristic. This discordance between studies requires further investigation, including into  
14 the relative opioid doses received by naïve vs non-naïve patients, and the default dosing applied in the  
15 clinical setting being studied. It may be that opioid naivety is protective in the real-world practice  
16 settings where clinicians know to utilize a lower default starting dosage to effectively control pain in  
17 patients who have not developed tolerance. In contrast, non-opiate naïve patients may have  
18 experienced increased risk of OIVI from higher starting doses and increased rate of escalating  
19 supplemental doses needed to control pain. Of the remaining predictors in our model, Pawasaukas et  
20 al<sup>37</sup> was the only previous model to include BMI and respiratory disease. None of the previous models  
21 included surgery (understandable for the risk model targeting medical hospitalizations only<sup>24</sup>), or PCA  
22 basal rate (although one did identify receipt of long-acting oxycodone or as-needed hydromorphone as  
23 a risk factor, which is physiologically similar).<sup>16</sup> Risk factors they identified and included that were not a  
24 part of our model include congestive heart failure,<sup>22 24</sup> psychosis or depression,<sup>24</sup> opioid  
25 abuse/dependence,<sup>24</sup> non-opioid drug abuse/dependence,<sup>24</sup> and presence on admission of respiratory  
26 failure, shock/hypotension on admission, acidosis, or neurologic failure.<sup>24</sup> Despite these differences, the  
27 performance of our risk model and the previous models is similar: both the PRODIGY model reported  
28 and the risk model targeting medical hospitalized patients reported c-statistics of 0.68-0.71,<sup>22 24</sup> which

1  
2  
3 our model modestly out-performed at 0.755, while the remaining risk model, which was developed from  
4 a small single center study, achieved a c-statistic of 0.86.<sup>16</sup> The PRODIGY score showed greater  
5 separation in risk for OIRD between its low, medium, and high risk score categories (24%, 42%, and  
6 65%<sup>22</sup> compared to our <5%, 5-15%, and >15%), but this is likely explained by their having examined  
7 respiratory depression detected by continuous pulse oximetry and capnography monitoring, rather than  
8 the clinically relevant potentially life-threatening events requiring naloxone reversal we examined.  
9  
10  
11  
12  
13  
14  
15

16 Some limitations should be kept in mind when interpreting our results. First, while our study  
17 sample was large and drawn from 12 acute care hospitals, it was nonetheless drawn from a single  
18 health care system. To the extent that risk for oversedation is affected by institutional prescribing  
19 policies or clinical decision support tools, monitoring schedules/equipment/staffing resources, and  
20 similar structural considerations governed at the health care system level, our findings may be less  
21 generalizable to all other settings. The differences noted in the risk factors included among the risk  
22 scores that have been developed to date – with all models showing good discrimination – indicates that  
23 there is further work to be done explain these discrepancies. Second, as was noted by the developers  
24 of a previous risk score focusing on oversedation or OIRD events identified through naloxone  
25 reversal,<sup>24</sup> the rarity of this adverse outcome keeps the positive predictive value of even a risk score  
26 with good discrimination relatively low. Thus, while the risk score offers important value in terms of  
27 identifying patients at increased risk for OIRD or oversedation, care must still be taken in selecting  
28 mechanisms for mitigating that risk, to avoid issues such as alarm fatigue that have been reported as  
29 barriers to increased monitoring (human or electronic) to catch earlier signs of oversedation and  
30 prevent its progression.<sup>8</sup> Another factor to be kept in mind with identifying OIRD events through  
31 naloxone reversal in an retrospective study is that staff may have had inherent biases related to their  
32 perceptions of patients' risk that made them more likely to diagnose oversedation and administer  
33 naloxone in some groups than others that cannot be captured in our data. However, such effects are  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 likely to be small, and do reflect the real-world setting in which this risk score was developed and will be  
4  
5 applied.  
6  
7

8 Recommendations included in national guidelines on monitoring for OIRD and oversedation  
9  
10 include that “all patients who will receive opioids undergo a comprehensive assessment of level of  
11  
12 individual risk before initiation of opioid therapy.”<sup>10</sup> While the guidelines go on to suggest that a risk  
13  
14 factor checklist be integrated into the electronic health record to assist with this comprehensive  
15  
16 assessment and its documentation, no guidance is provided on how clinicians should judge cumulative  
17  
18 risk for patients in whom multiple risk factors are present. The ORC risk score we have developed is a  
19  
20 tool to achieve this, and unlike previous studies, is applicable to all adult patients admitted to an acute  
21  
22 care hospital. Future research should include evaluation of the ORC risk score for use in ambulatory  
23  
24 centers: as more procedures that have traditionally been performed in the high resource setting of  
25  
26 acute care hospitals transition to such settings,<sup>38</sup> where the availability of staff and resources to monitor  
27  
28 patients for or respond to events of OIRD or oversedation may be more limited, identification of high-  
29  
30 risk patients may be even more critical for maintaining patient safety.  
31  
32  
33

34 Beyond application to targeted monitoring of high-risk patients for early detection of and  
35  
36 intervention to prevent progression of OIRD and oversedation events, our results suggest opportunities  
37  
38 for prevention through interventions aimed at prescribing clinicians – for example, clinical decision  
39  
40 support utilizing the ORC offered when concurrent prescriptions for opioids and other sedating  
41  
42 medications are entered. Such preventive approaches will be critical to achieving sustained  
43  
44 improvement, as the high rate of false positive alarms – even among patients at high risk for OIRD and  
45  
46 oversedation – leave strategies that focus exclusively on monitoring and early detection vulnerable to  
47  
48 alarm fatigue and competing priorities for attention among staff tasked with responding.  
49  
50  
51  
52

53 **Ethical Statement:**  
54  
55  
56  
57



1  
2  
3 This study involves human participants and was approved the Baylor Scott & White Research Institute  
4 Institutional Review Board (IRB 018-761) with a waiver of informed consent.  
5  
6  
7

### 8 9 **Funding:**

10  
11 This work was funded by the Baylor Health Care System Foundation. The funder played no role in this  
12 study, and the research team operated independently.  
13  
14  
15

### 16 17 **Contributions of the authors:**

18  
19 Garrett (study guarantor): study concept, study design, data analysis, data interpretation, drafting the  
20 manuscript  
21  
22

23  
24 Vanston: data collection, data management, revising the manuscript  
25

26  
27 da Graca: literature search, drafting the manuscript

28  
29 Ogola: data collection, data analysis, figures and tables, drafting the manuscript

30  
31 Kouznetsova: study concept, revising the manuscript

32  
33 Cassity: data collection, revising the manuscript

34  
35 Hall: data collection, data management, revising the manuscript

36  
37 Qui: data collection, data management, revising the manuscript  
38  
39  
40

41 **Transparency declaration:** I, Dr. John Garrett, affirm that the manuscript is an honest, accurate, and  
42 transparent account of the study being reported; that no important aspects of the study have been  
43 omitted; and that any discrepancies from the study as planned) have been explained.  
44  
45  
46

47  
48 **Data sharing:** Please contact the corresponding author with any requests.  
49  
50

51  
52 **Conflicts of interest:** The authors have no conflicts of interest to declare.  
53  
54  
55  
56  
57

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## REFERENCES

1. Lee LA, Caplan RA, Stephens LS, et al. Postoperative opioid-induced respiratory depression: a closed claims analysis. *Anesthesiology* 2015;122(3):659-65. doi: 10.1097/ALN.0000000000000564 [published Online First: 2014/12/24]
2. The Joint Commission. Safe use of opioids in hospitals. *Sentinel Event Alert* 2012;49:1-5.
3. Jarzyna D, Jungquist CR, Pasero C, et al. American Society for Pain Management Nursing guidelines on monitoring for opioid-induced sedation and respiratory depression. *Pain Manag Nurs* 2011;12(3):118-45 e10. doi: 10.1016/j.pmn.2011.06.008 [published Online First: 2011/09/07]
4. Herzig SJ, Rothberg MB, Cheung M, et al. Opioid utilization and opioid-related adverse events in nonsurgical patients in US hospitals. *J Hosp Med* 2014;9(2):73-81. doi: 10.1002/jhm.2102 [published Online First: 2013/11/15]
5. Kessler ER, Shah M, Gruschkus SK, et al. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. *Pharmacotherapy* 2013;33(4):383-91. doi: 10.1002/phar.1223 [published Online First: 2013/04/05]
6. Minkowitz HS, Gruschkus SK, Shah M, et al. Adverse drug events among patients receiving postsurgical opioids in a large health system: risk factors and outcomes. *Am J Health Syst Pharm* 2014;71(18):1556-65. doi: 10.2146/ajhp130031 [published Online First: 2014/09/01]
7. Gupta RA, Edwards DA. Monitoring for opioid-induced respiratory depression. *APSF News* 2018;32:70-72.
8. Jungquist CR, Willens JS, Dunwoody DR, et al. Monitoring for opioid-induced advancing sedation and respiratory depression: ASPMN membership survey of current practice. *Pain Manag Nurs* 2014;15(3):682-93. doi: 10.1016/j.pmn.2013.12.001 [published Online First: 2014/03/25]

- 1  
2  
3 9. Practice Guidelines for the Prevention, Detection, and Management of Respiratory Depression  
4  
5 Associated with Neuraxial Opioid Administration: An Updated Report by the American Society of  
6  
7 Anesthesiologists Task Force on Neuraxial Opioids and the American Society of Regional  
8  
9 Anesthesia and Pain Medicine. *Anesthesiology* 2016;124(3):535-52. doi:  
10  
11 10.1097/ALN.0000000000000975 [published Online First: 2015/12/15]  
12  
13  
14 10. Jungquist CR, Quinlan-Colwell A, Vallerand A, et al. American Society for Pain Management  
15  
16 Nursing Guidelines on Monitoring for Opioid-Induced Advancing Sedation and Respiratory  
17  
18 Depression: Revisions. *Pain Manag Nurs* 2020;21(1):7-25. doi: 10.1016/j.pmn.2019.06.007  
19  
20 [published Online First: 2019/08/05]  
21  
22 11. The Joint Commission. Joint Commission Enhances Pain Assessment and Management  
23  
24 Requirements for Accredited Hospitals. *The Joint Commission Perspectives* 2017;37(7):2-4.  
25  
26 12. Gupta K, Prasad A, Nagappa M, et al. Risk factors for opioid-induced respiratory depression and  
27  
28 failure to rescue: a review. *Curr Opin Anaesthesiol* 2018;31(1):110-19. doi:  
29  
30 10.1097/ACO.0000000000000541 [published Online First: 2017/11/10]  
31  
32  
33 13. Gordon DB, Pellino TA. Incidence and characteristics of naloxone use in postoperative pain  
34  
35 management: a critical examination of naloxone use as a potential quality measure. *Pain Manag*  
36  
37 *Nurs* 2005;6(1):30-6. doi: 10.1016/j.pmn.2004.12.003 [published Online First: 2005/05/27]  
38  
39 14. Overdyk FJ, Carter R, Maddox RR, et al. Continuous oximetry/capnometry monitoring reveals  
40  
41 frequent desaturation and bradypnea during patient-controlled analgesia. *Anesth Analg*  
42  
43 2007;105(2):412-8. doi: 10.1213/01.ane.0000269489.26048.63 [published Online First:  
44  
45 2007/07/25]  
46  
47 15. Overdyk F, Dahan A, Roozkrans M, et al. Opioid-induced respiratory depression in the acute care  
48  
49 setting: a compendium of case reports. *Pain Manag* 2014;4(4):317-25. doi: 10.2217/pmt.14.19  
50  
51 [published Online First: 2014/10/11]  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 16. Brant JM, Stringer L, Jurkovich LR, et al. Predictors of oversedation in hospitalized patients. *Am J*  
4 *Health Syst Pharm* 2018;75(18):1378-85. doi: 10.2146/ajhp170558 [published Online First:  
5 2018/09/08]  
6  
7  
8  
9  
10 17. Gupta K, Nagappa M, Prasad A, et al. Risk factors for opioid-induced respiratory depression in  
11 surgical patients: a systematic review and meta-analyses. *BMJ Open* 2018;8(12):e024086. doi:  
12 10.1136/bmjopen-2018-024086 [published Online First: 2018/12/16]  
13  
14  
15  
16 18. Ramachandran SK, Haider N, Saran KA, et al. Life-threatening critical respiratory events: a  
17 retrospective study of postoperative patients found unresponsive during analgesic therapy. *J*  
18 *Clin Anesth* 2011;23(3):207-13. doi: 10.1016/j.jclinane.2010.09.003 [published Online First:  
19 2011/05/17]  
20  
21  
22  
23  
24 19. Weingarten TN, Herasevich V, McGlinch MC, et al. Predictors of Delayed Postoperative Respiratory  
25 Depression Assessed from Naloxone Administration. *Anesth Analg* 2015;121(2):422-9. doi:  
26 10.1213/ANE.0000000000000792 [published Online First: 2015/05/21]  
27  
28  
29  
30  
31 20. Weingarten TN, Chong EY, Schroeder DR, et al. Predictors and outcomes following naloxone  
32 administration during Phase I anesthesia recovery. *J Anesth* 2016;30(1):116-22. doi:  
33 10.1007/s00540-015-2082-0 [published Online First: 2015/10/10]  
34  
35  
36  
37 21. Overdyk FJ, Dowling O, Marino J, et al. Association of Opioids and Sedatives with Increased Risk  
38 of In-Hospital Cardiopulmonary Arrest from an Administrative Database. *PLoS One*  
39 2016;11(2):e0150214. doi: 10.1371/journal.pone.0150214 [published Online First: 2016/02/26]  
40  
41  
42  
43 22. Khanna AK, Bergese SD, Jungquist CR, et al. Prediction of Opioid-Induced Respiratory Depression  
44 on Inpatient Wards Using Continuous Capnography and Oximetry: An International Prospective,  
45 Observational Trial. *Anesth Analg* 2020;131(4):1012-24. doi: 10.1213/ANE.0000000000004788  
46  
47  
48  
49 [published Online First: 2020/09/15]  
50  
51  
52 23. Khanna AK, Overdyk FJ, Greening C, et al. Respiratory depression in low acuity hospital settings-  
53 Seeking answers from the PRODIGY trial. *J Crit Care* 2018;47:80-87. doi:  
54 10.1016/j.jcrc.2018.06.014 [published Online First: 2018/06/25]  
55  
56  
57

- 1  
2  
3 24. Herzig SJ, Stefan MS, Pekow PS, et al. Risk Factors for Severe Opioid-Related Adverse Events in  
4 a National Cohort of Medical Hospitalizations. *J Gen Intern Med* 2020;35(2):538-45. doi:  
5 10.1007/s11606-019-05490-w [published Online First: 2019/11/16]  
6  
7  
8  
9 25. Zedler B, Xie L, Wang L, et al. Development of a Risk Index for Serious Prescription Opioid-Induced  
10 Respiratory Depression or Overdose in Veterans' Health Administration Patients. *Pain Med*  
11 2015;16(8):1566-79. doi: 10.1111/pme.12777 [published Online First: 2015/06/17]  
12  
13  
14  
15 26. Zedler BK, Saunders WB, Joyce AR, et al. Validation of a Screening Risk Index for Serious  
16 Prescription Opioid-Induced Respiratory Depression or Overdose in a US Commercial Health  
17 Plan Claims Database. *Pain Med* 2018;19(1):68-78. doi: 10.1093/pm/pnx009 [published Online  
18 First: 2017/03/25]  
19  
20  
21  
22  
23 27. Filardo G, Hamilton C, Hamman B, et al. Categorizing BMI may lead to biased results in studies  
24 investigating in-hospital mortality after isolated CABG. *J Clin Epidemiol* 2007;60(11):1132-9. doi:  
25 10.1016/j.jclinepi.2007.01.008 [published Online First: 2007/10/17]  
26  
27  
28  
29 28. Harrell FE. Regression Modeling Strategies: With applications to Linear Models, Logistic  
30 Regression and Survival Analysis. New York: Springer-Verlag 2001.  
31  
32  
33 29. Bosilkovska M, Walder B, Besson M, et al. Analgesics in patients with hepatic impairment:  
34 pharmacology and clinical implications. *Drugs* 2012;72(12):1645-69. doi: 10.2165/11635500-  
35 000000000-00000 [published Online First: 2012/08/08]  
36  
37  
38  
39 30. Dean M. Opioids in renal failure and dialysis patients. *J Pain Symptom Manage* 2004;28(5):497-  
40 504. doi: 10.1016/j.jpainsymman.2004.02.021 [published Online First: 2004/10/27]  
41  
42  
43 31. Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids  
44 and benzodiazepines and overdose: retrospective analysis. *BMJ* 2017;356:j760. doi:  
45 10.1136/bmj.j760 [published Online First: 2017/03/16]  
46  
47  
48  
49 32. Davies EA, O'Mahony MS. Adverse drug reactions in special populations - the elderly. *Br J Clin*  
50 *Pharmacol* 2015;80(4):796-807. doi: 10.1111/bcp.12596 [published Online First: 2015/01/27]  
51  
52  
53  
54  
55  
56  
57

- 1  
2  
3 33. Lam KK, Kunder S, Wong J, et al. Obstructive sleep apnea, pain, and opioids: is the riddle solved?  
4  
5 *Curr Opin Anaesthesiol* 2016;29(1):134-40. doi: 10.1097/ACO.0000000000000265 [published  
6  
7 Online First: 2015/11/07]  
8
- 9 34. Khelemsky Y, Kothari R, Campbell N, et al. Incidence and Demographics of Post-Operative  
10  
11 Naloxone Administration: A 13-Year Experience at a Major Tertiary Teaching Institution. *Pain*  
12  
13 *Physician* 2015;18(5):E827-9. [published Online First: 2015/10/03]  
14  
15
- 16 35. Cashman JN, Dolin SJ. Respiratory and haemodynamic effects of acute postoperative pain  
17  
18 management: evidence from published data. *Br J Anaesth* 2004;93(2):212-23. doi:  
19  
20 10.1093/bja/aeh180 [published Online First: 2004/06/01]  
21
- 22 36. Crowgey TR, Dominguez JE, Peterson-Layne C, et al. A retrospective assessment of the incidence  
23  
24 of respiratory depression after neuraxial morphine administration for postcesarean delivery  
25  
26 analgesia. *Anesth Analg* 2013;117(6):1368-70. doi: 10.1213/ANE.0b013e3182a9b042  
27  
28 [published Online First: 2013/11/22]  
29
- 30 37. Pawasauskas J, Stevens B, Youssef R, et al. Predictors of naloxone use for respiratory depression  
31  
32 and oversedation in hospitalized adults. *Am J Health Syst Pharm* 2014;71(9):746-50. doi:  
33  
34 10.2146/ajhp130568 [published Online First: 2014/04/16]  
35  
36
- 37 38. DeCook CA. Outpatient Joint Arthroplasty: Transitioning to the Ambulatory Surgery Center. *J*  
38  
39 *Arthroplasty* 2019;34(7S):S48-S50. doi: 10.1016/j.arth.2019.01.006 [published Online First:  
40  
41 2019/02/19]  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure Legends**

Figure 1. Inclusion and exclusion of hospital encounters for the development of the Oversedation Risk Criteria (ORC) score.

Figure 2. Risk of opioid-induced respiratory depression or oversedation by body mass index (BMI)

Figure 3. Risk of opioid-induced respiratory depression or oversedation by Oversedation Risk Criteria (ORC) score.

For peer review only



## TABLES

**Table 1.** Patient demographic and clinical characteristics and outcomes for inpatients who did vs did not experience an opioid-related oversedation event

	Oversedation (N=293)	No Oversedation (N=162,897)	P-value
Age (years)			< 0.001
<50	52 (17.7%)	63361 (38.9%)	
50-59	54 (18.4%)	26319 (16.2%)	
60-69	74 (25.3%)	31329 (19.2%)	
70+	113 (38.6%)	41888 (25.7%)	
Sex (Female)	191 (65.2%)	99562 (61.1%)	0.154
Race			0.618
White	230 (78.5%)	124351 (76.3%)	
Black	46 (15.7%)	29139 (17.9%)	
Other	17 (5.8%)	9407 (5.8%)	
Hispanic ethnicity	34 (11.6%)	25330 (15.5%)	0.063
BMI - Mean $\pm$ SD (kg.m <sup>2</sup> )	30.1 $\pm$ 10.3	30.0 $\pm$ 8.2	0.745
Concurrent administration of sedating medication	267 (91.1%)	95495 (58.6%)	< 0.001
Antihistamine	73 (24.9%)	29952 (18.4%)	0.004
Renal Insufficiency diagnosis	141 (48.1%)	46415 (28.5%)	< 0.001
Liver Insufficiency diagnosis	189 (64.5%)	67917 (41.7%)	< 0.001
Chronic obstructive pulmonary disease	73 (24.9%)	20592 (12.6%)	< 0.001
Heart failure	72 (24.6%)	25506 (15.7%)	< 0.001
Thoracic or large incision that interferes with adequate ventilation	20 (6.8%)	8577 (5.3%)	0.232
Positive sleep apnea screen: Snore	95 (32.9%)	40018 (24.9%)	< 0.001
Positive sleep apnea screen: Doze off	76 (26.3%)	22167 (13.8%)	< 0.001
Live alone	4 (1.4%)	603 (0.4%)	0.018
Smoking History			0.014
Non-Smoker	152 (51.9%)	95410 (58.6%)	
Former Smoker	90 (30.7%)	38785 (23.8%)	
Current Smoker	40 (13.7%)	24733 (15.2%)	
Unknown/Missing	11 (3.8%)	3969 (2.4%)	
Surgery	148 (50.5%)	55262 (33.9%)	< 0.001
Untreated obstructive sleep apnea	55 (19.4%)	18846 (12.0%)	< 0.001
Opioid Naive	155 (52.9%)	105519 (64.8%)	< 0.001
PCA basal	7 (2.4%)	1066 (0.7%)	< 0.001
Days on opioids - Median (Q1, Q3)	7.0 (4.0, 13.0)	3.0 (2.0, 5.0)	< 0.001
Disposition			< 0.001
Expired	20 (6.8%)	4743 (2.9%)	
Home	140 (47.8%)	128709 (79.0%)	
Transferred to other facilities	133 (45.4%)	29445 (18.1%)	
Length of Stay (days) - Median (Q1, Q3)	9.0 (5.0, 15.0)	3.0 (2.0, 6.0)	< 0.001

BMI – body mass index; SD – standard deviation; Q - quartile

**Table 2.** Associations between risk factors included in the full and reduced models for predicting opioid-induced respiratory depression or oversedation.


Risk factors	HR (95%CI) and P-value	
	Full Model	Reduced Model
Age (years)		
50-59	1.39 (0.91 - 2.13) p = 0.13	1.39 (0.91 - 2.12) p = 0.13
60-69	1.52 (1.01 - 2.28) p = 0.04	1.54 (1.03 - 2.30) p = 0.03
70+	1.69 (1.13 - 2.52) p = 0.01	1.75 (1.19 - 2.57) p = <.01
Sex (Female vs. Male)	1.59 (1.21 - 2.09) p = <.01	1.60 (1.23 - 2.09) p = <.01
Race		
Black vs White	0.83 (0.57 - 1.20) p = 0.31	
Other vs White	1.21 (0.70 - 2.10) p = 0.49	
Hispanic ethnicity	1.06 (0.71 - 1.58) p = 0.78	
Smoking History		
Former vs Never	1.03 (0.77 - 1.38) p = 0.84	
Current vs Never	0.86 (0.58 - 1.28) p = 0.47	
BMI (kg/m <sup>2</sup> )		
(BMI<26)	1.02 (1.00 - 1.03) p = 0.07	1.02 (1.00 - 1.04) p = 0.05
(BMI >= 26)	0.68 (0.48 - 0.96) p = 0.03	0.69 (0.49 - 0.97) p = 0.03
Antihistamine	0.91 (0.68 - 1.22) p = 0.53	
Chronic obstructive pulmonary disease	1.57 (1.14 - 2.15) p = <.01	1.48 (1.10 - 1.99) p = <.01
Concurrent administration of sedating medication	3.89 (2.48 - 6.10) p = <.01	3.88 (2.48 - 6.06) p = <.01
Heart Failure	0.89 (0.64 - 1.22) p = 0.47	
Live alone	2.55 (0.63 - 10.29) p = 0.19	
Liver insufficiency diagnosis	1.60 (1.21 - 2.10) p = <.01	1.62 (1.23 - 2.12) p = <.01
Opioid Naive	0.76 (0.59 - 0.97) p = 0.03	0.74 (0.58 - 0.95) p = 0.02
PCA Basal	1.87 (0.82 - 4.26) p = 0.13	1.96 (0.87 - 4.46), p = 0.10
Renal insufficiency	1.40 (1.07 - 1.85) p = 0.02	1.35 (1.03 - 1.76) p = 0.03
Positive sleep apnea screen (Snore or Doze-off)	1.42 (1.08 - 1.87) p = 0.01	1.45 (1.11 - 1.88) p = <.01
Surgery	1.57 (1.20 - 2.04) p = <.01	1.53 (1.18 - 1.98) p = <.01
Thoracic or large incision that interferes with adequate ventilation	0.68 (0.41 - 1.12) p = 0.13	
Untreated obstructive sleep apnea	1.18 (0.84 - 1.66) p = 0.34	
BMI – body mass index; CI – confidence interval; HR – hazard ratio		

**Table 3. Medications with sedating properties prescribed concomitantly with opioids in patients who experienced an opioid-related oversedation event**

Drug type/category	n (%)
Benzodiazepine	245 (29.0)
Antidepressants	186 (22.0)
Gamma-aminobutyric acid analog	124 (14.7)
Miscellaneous anxiolytic, sedative and hypnotic (sleep aids)	86 (10.2)
Antipsychotic	69 (8.2)
Antihistamine	68 (8.0)
Anticonvulsant	38 (4.5)
Dopaminergic anti-Parkinsonism agents	15 (1.8)
Barbiturate	6 (0.7)
Phenothiazine antiemetics	5 (0.6)
Carbonic anhydrase inhibitor	3 (0.4)

**Table 4. Points assigned per risk factor in the Oversedation Risk Criteria (ORC) score**

<b>Risk factor</b>	<b>Points</b>
Age (years)	
< 50	0
50-59	1
60+	2
Sex - Female	2
BMI (kg/m <sup>2</sup> )	
10	5
20	2
30	0
40	1
50	2
60	3
70	4
80	5
90	6
100	7
110	8
120	9
130	10
Concurrent administration of sedating medication	5
Renal Insufficiency	1
Liver Insufficiency	2
Chronic obstructive pulmonary disease	1
Sleep Apnea	2
Surgery within 24 hours	2
Not Opioid Naive	1
PCA Basal	3



Inclusion and exclusion of hospital encounters for the development of the Oversedation Risk Criteria (ORC) score.

91x85mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2. Risk of opioid-induced respiratory depression or oversedation by body mass index (BMI)  
169x152mm (300 x 300 DPI)




Figure 3. Risk of opioid-induced respiratory depression or oversedation by Oversedation Risk Criteria (ORC) score.

237x135mm (300 x 300 DPI)

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7-8
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8
Bias	9	Describe any efforts to address potential sources of bias	8-9
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	8-9
		(c) Explain how missing data were addressed	23
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	n/a

Continued on next page



<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	27, Fig 1
		(b) Give reasons for non-participation at each stage	Fig 1
		(c) Consider use of a flow diagram	Fig 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	n/a
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	Tables 1
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2
		(b) Report category boundaries when continuous variables were categorized	Table 2
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).